Clinical Trials of Cellular Therapies in Solid Tumors.

ABSTRACT: In the past years cancer treatments have drastically changed, mainly due to the development of immune checkpoint inhibitors capable of immune modulation in vivo, thus providing major clinical benefit in a number of malignancies. Simultaneously, considerable technical refinements have opened new prospects for the development of immune cell-based medicinal products and unprecedented success with chimeric antigen receptor (CAR)-T cells targeting B-cell hematologic malignancies has been obtained. However, T cell therapies introduced and performed in the field of solid tumors have produced so far only limited responses in selected patient populations. This standstill is attributable to the difficulty in identifying target antigens which are homogeneously expressed by all tumor cells while absen

SUBMITTER: Secondino S 

PROVIDER: S-EPMC10377409 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature